The updated guidelines from American Society for Radiation Oncology also address the treatment of older and medically frail ...

Researchers explore glioblastoma's genetic complexity using innovative spatial profiling, aiming to enhance treatment ...

A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a ...

The University of Virginia School of Medicine’s Harald Sontheimer, PhD, and Stanford’s Michelle Monje, MD, PhD, have received ...

A team of NYU chemists and physicists are using cutting-edge tools—holographic microscopy and super-resolution imaging—to unlock how cells build and grow tiny, dynamic droplets known as biomolecular ...

The fluorescent labeling compound—dubbed "Sialyl Lewis Yellow"—was developed by an international team led from the Pohang University of Science and Technology in South Korea. It works by binding to ...

Researchers and biomedical engineers from Dartmouth Health, Dartmouth Cancer Center and the Thayer School of Engineering at ...

In terms of photosensitization, both KillerRed and its monomeric variant (SuperNova) generate reactive oxygen species upon irradiation with green light to effect cell killing 13,14. Applications of ...

T cells transformed in vivo to target B cells could widen the scope of diseases treated by chimeric antigen receptor T-cell therapy.

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed.

They are mapping out interactions between tumour cells and the nerve cells surrounding them – and shattering the long-held belief that these are of little significance.

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study.